Table 2.

Number of subjects experiencing a seroconversion (≥ 4-fold rise in antibody titer) vs. nine common respiratory viruses during the entire study period; 191 subjects had serum samples available both at baseline and end-of-study and were thus included in the analysis. Totals are given both as proportion of subjects in each group experiencing seroconversion/cold season and, since individuals could seroconvert to > one virus, the rate of seroconversions/cold season by group is also shown.

Virus	CVT-E002 (n=91)	Placebo (n=100)	p-value
influenza A	1	0	0.48
influenza B	1	1	1.0
respiratory syncytial virus	1	1	1.0
human metapneumovirus	6	1	0.06
parainfluenza type 1	1	1	1.0
parainfluenza type 2	1	0	0.48
parainfluenza type 3	1	1	1.0
coronavirus 229E	3	1	0.35
coronavirus OC43	5	1	0.10
Proportion of subjects with seroconversion/cold season	(1591) 16%	(7/100) 7%	0.04
Seroconversion rate/cold season	0.22	0.07	0.005